Biotechnology

A new partnership aims to replace needles with pills for a powerful class of drugs, using advanced AI to solve a multi-billion dollar challenge in medicine.

Laprophan's acquisition of Rivopharm is more than a deal; it's a strategic blueprint for emerging market players aiming for the global pharmaceutical stage.

As federal support for science wanes, the National Cancer Center adds top minds from Stanford and Harvard to identify and fund the next wave of cancer cures.

Gelteq aims to replace needles with its ingestible gel, targeting diabetes and more. But can it balance this lofty goal with near-term revenue and tight finances?

An Israeli biotech just published a patent for a 'mucoadhesive' gel that makes drugs stick inside the nose. It's a key step in a multi-billion dollar race.

A key update to a revolutionary cancer therapy reduces post-treatment restrictions, signaling a new era of patient-centric care and system efficiency in Canada.

Insilico Medicine's AI-designed drug, ISM8969, enters human trials, targeting chronic neuroinflammation by crossing the elusive blood-brain barrier.

The communications firm adds three seasoned experts, a strategic move to guide biotech and pharma clients through increasingly volatile capital markets.

Rare complete responses in deadly pancreatic cancer hint at a powerful new synergy, but can Elicio Therapeutics secure the funding to prove its theory?

As giants rule the obesity market, small-cap MetaVia pitches a novel dual-agonist and a first-in-class MASH drug. Can its science win the day?

With a new $400M debt facility, Dyne Therapeutics is accelerating two promising drugs for DMD and DM1, showcasing the power of strategic, non-dilutive financing.

Verastem Oncology's combo therapy posts impressive early data in a notoriously deadly cancer, revealing a shrewd strategy for tackling drug resistance.

With a promising drug and a fortified war chest, Trevi Therapeutics’ upcoming conference tour is a calculated move to conquer a vast, unmet medical need.

A landmark grant and trial expansion signal a pivotal shift in Parkinson's research, blending genetic targeting, global collaboration, and digital health.

Gene therapy firm uniQure plans a 2026 FDA submission for AMT-130, a potential first disease-modifying treatment for Huntington's, on an accelerated track.

New research reveals that custom 3D braces can actively correct spinal curves, not just prevent them from worsening. This paradigm shift in non-surgical care offers new hope.

21 doctors from one practice in a "Top Doctors" Hall of Fame is a headline. But what does it reveal about building trust and innovation in cancer care?

Aker BioMarine's pact with ENGIE isn't just about PR. It's a move to hourly clean energy matching, a strategic play that redefines operational sustainability.

At BIO 2026, Israeli biotech Can-Fite seeks crucial partnerships for its late-stage cancer and inflammation drugs, built on a unique, safety-focused platform.

New data on ersodetug reveals a calculated strategy to conquer hyperinsulinism, balancing patient hope with the harsh realities of the biotech market.